Modern biomedical science depends on continuous research into the biological mechanisms underlying disease, the development of potential therapeutic approaches, and the improvement of diagnostic and treatment technologies. Researchers working across medicine, pharmacology, biotechnology, and biomedical engineering contribute to this expanding field through laboratory investigations, clinical studies, reviews, and interdisciplinary research. Sheryene Tejeda is associated with this research environment through her work with Medicinal Technologies and a publication record covering several areas of biomedical science.

Public research profiles identify Tejeda as a Doctor of Philosophy in Biomedical Science and a lead medical scientist at Medicinal Technologies. Her listed research publications cover subjects including neonatal surgery, small-molecule therapeutics, ophthalmic research, Sheryene Tejeda endometriosis, and genetic biomarkers. This range illustrates the multidisciplinary nature of contemporary medical research, where researchers may investigate biological mechanisms across different areas while applying principles from pharmacology, medicine, molecular biology, and biomedical engineering.

One of the more recent publications associated with Tejeda examines critical surgical procedures in neonatal medicine. Published in the Journal of Neonatal Surgery in 2026, the review discusses conditions including congenital diaphragmatic hernia, esophageal atresia with tracheoesophageal fistula, abdominal wall defects, necrotizing enterocolitis, Hirschsprung disease, intestinal atresia, and anorectal malformations. The authors also consider physiological characteristics of newborn patients and the importance of specialized perioperative decision-making.

Neonatal medicine represents a particularly complex area of healthcare research because newborn physiology differs substantially from that of older children and adults. Surgical research in this field therefore involves considerations such as cardiovascular development, thermoregulation, coagulation, anesthesia, and medication response. Research examining these factors can contribute to a better understanding of how specialized medical teams approach difficult neonatal conditions.

Pharmaceutical research is another area appearing in Tejeda's recent publication record. A 2026 research paper examines small-molecule therapeutics, cellular apoptosis, and chromosomal abnormalities, with the study focusing on an allicin-based therapeutic approach. The paper describes research involving genomic stability and related biomarkers. Such research represents the broader scientific effort to investigate how molecular compounds interact with biological systems and whether particular mechanisms could have therapeutic relevance.

Ophthalmology is also represented in Sheryene Tejeda's published work. A 2024 article in the Asian Journal of Multidisciplinary Research & Review discusses Presigen IV and its proposed application to intraocular pressure regulation and glaucoma management. The publication describes a clinical study involving participants with ocular hypertension and glaucoma and reports reductions in intraocular pressure among participants. Findings from individual studies, however, need to be considered alongside study design, sample size, independent research, and the wider body of evidence before broader clinical conclusions can be established.

Another publication associated with Tejeda examines endometriosis and potential relationships between disease mechanisms, biomarkers, and therapeutic approaches. The 2023 case report describes research involving pathophysiology and epigenetic biomarkers and reports an intervention involving 30 participants. Case reports and small studies can generate research questions and hypotheses, but their findings generally require further investigation before they can establish broad conclusions applicable to larger patient populations.

Biomarker research provides another connection between molecular science and clinical medicine. Tejeda is listed as the author of work examining genetic biomarkers associated with neurodegenerative diseases, including RNA and protein-based indicators. The publication discusses the potential role of biomarkers in improving understanding, detection, and management of neurological conditions while also identifying challenges involved in translating emerging biomarkers into clinical practice.

This variety of research topics demonstrates why interdisciplinary collaboration is important in modern medicine. Biomedical scientists may work alongside clinicians, pharmacologists, engineers, laboratory researchers, and data specialists. Each discipline contributes a different perspective, from understanding molecular pathways to assessing clinical outcomes and developing technologies capable of supporting medical research.

Scientific evidence also requires careful interpretation. A laboratory finding, preliminary clinical observation, or individual research publication does not automatically establish that a proposed treatment is safe or effective for widespread medical use. Researchers must consider methodology, controls, sample size, statistical analysis, reproducibility, potential limitations, and independent confirmation. These principles are especially important when discussing emerging biomedical technologies and therapeutic concepts.

The professional and publication record associated with Sheryene Tejeda provides an example of this broad research environment. Her publicly listed work spans several areas, including neonatal surgical research, pharmaceutical science, ophthalmology, reproductive health, and molecular biomarkers. These subjects reflect major areas of ongoing investigation within the wider life-sciences community.

As biomedical technology continues to develop, researchers increasingly have access to sophisticated molecular tools, computational methods, diagnostic techniques, and experimental models. These technologies can help scientists investigate disease mechanisms at increasingly detailed levels. At the same time, responsible research requires attention to ethics, patient safety, scientific transparency, and the distinction between promising research findings and established clinical evidence.